CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Baricitinib or AnakinraWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug611 Cannabis, Medical Wiki 1.00

Correlated MeSH Terms (24)

Name (Synonyms) Correlation
D000070627 Chronic Traumatic Encephalopathy NIH 1.00
D000690 Amyotrophic Lateral Sclerosis NIH 1.00
D016472 Motor Neuron Disease NIH 1.00
D005879 Tourette Syndrome NIH 1.00
D012640 Seizures NIH 0.71
D000755 Anemia, Sickle Cell NIH 0.71
D001714 Bipolar Disorder NIH 0.71
D005356 Fibromyalgia NIH 0.58
D001927 Brain Diseases NIH 0.50
D010300 Parkinsonian NIH 0.50
D003424 Crohn Disease NIH 0.45
D000070642 Brain Injuries, Traumatic NIH 0.38
D015212 Inflammatory Bowel Diseases NIH 0.38
D059350 Chronic Pain NIH 0.35
D001930 Brain Injuries, NIH 0.33
D012598 Scoliosi NIH 0.30
D009103 Multiple Sclerosis NIH 0.29
D040921 Stress Disorders, Traumatic NIH 0.19
D014947 Wounds and Injuries NIH 0.19
D013313 Stress Disorders, Post-Traumatic NIH 0.18
D004194 Disease NIH 0.17
D013577 Syndrome NIH 0.10
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (8)

Name (Synonyms) Correlation
HP:0006802 Abnormal anterior horn cell morphology HPO 1.00
HP:0007354 Amyotrophic lateral sclerosis HPO 1.00
HP:0100754 Mania HPO 0.71
HP:0001250 Seizure HPO 0.58
HP:0001298 Encephalopathy HPO 0.50
HP:0100280 Crohn's disease HPO 0.45
HP:0002037 Inflammation of the large intestine HPO 0.38
HP:0012532 Chronic pain HPO 0.35

There is one clinical trial.

Clinical Trials

1 Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults

Retrospective clinical-epidemiological study aimed at characterizing COVID-19 disease in adults older than 70 years, hospitalized in the "Perpetuo Socorro" Hospital of Albacete (Spain) from 09/03/2020 until 20/04/2020. Secondary objectives will be to analyze clinical-epidemiological characteristics of COVID-19 patients treated with Baricitinib or Anakinra, and to describe the efficacy and secondary effects of those drugs.

NCT04362943 COVID-19 Drug: Baricitinib or Anakinra

Primary Outcomes

Description: Mortality for all causes

Measure: Mortality

Time: 1 month

Secondary Outcomes

Description: Changes from admission to discharge thorax X-rays assessed by blinded radiologists

Measure: X-ray changes

Time: 1 month

Description: Changes from admission to discharge in Barthel index

Measure: Disability changes

Time: 1 month

Description: Changes from admission to discharge in Functional Ambulation Classification

Measure: Ambulation changes

Time: 1 month

Description: Changes from admission to discharge in lymphocyte count

Measure: lymphocyte count changes

Time: 1 month

Description: Changes from admission to discharge in C-Reactive Protein

Measure: C-Reactive Protein changes

Time: 1 month

Description: Changes from admission to discharge in Ferritin

Measure: Ferritin changes

Time: 1 month

Description: Changes from admission to discharge in D-Dimer

Measure: D-Dimer changes

Time: 1 month

No related HPO nodes (Using clinical trials)